Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a drug to market, showing an impressive disregard for shareholders as reasons for its prolonged existence kept being created.
After listening to management's presentation at HC Wainwright, I came away intrigued with their new royalty aggregation strategy (doing away with